Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.68 |
| ▸ | TLR4 | O00206 | 5/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.68 |
| ▸ | DRD2 | P14416 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277013 | 0.98 | ADRB2 (0.68) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL14582544 | 0.95 | ADRB2 (0.63) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL10123780 | 0.95 | ADRB2 (0.65) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL5375723 | 0.92 | ADRB2 (0.62) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL17946178 | 0.91 | ADRB2 (0.58) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL8199187 | 0.91 | ADRB2 (0.67) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL7997039 | 0.90 | ADRB2 (0.66) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL13204418 | 0.89 | ADRB2 (0.65) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL10108670 | 0.88 | ADRB2 (0.64) | ADRB2TLR4ADRB3DRD2MAPT | |
| SCHEMBL13964556 | 0.87 | ADRB2 (0.63) | ADRB2TLR4ADRB3DRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741700-B1 | Process for the preparation of carvedilol | IPCA LAB LTD (IN) | 2008-12-24 | — | — | EP | claimed |
| US-20080207726-A1 | Process for the purification of carvedilol or its salts thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | claimed |
| US-20070027202-A1 | Process for the preparation of carvedilol and its salts | IPCA LABORATORIES LIMITED (IN) | 2007-02-01 | — | — | US | claimed |
| EP-1741700-A1 | Process for the preparation of carvedilol | IPCA Laboratories Limited (IN) | 2007-01-10 | — | — | EP | claimed |
| WO-2015031914-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2015-03-05 | — | — | WO | disclosed |
| US-8058453-B2 | Process for the preparation of Carvedilol Form II | MATRIX LABORATORIES LTD. (IN) | 2011-11-15 | — | — | US | disclosed |
| US-8058453-B2 | Process for the preparation of Carvedilol Form II | MATRIX LABORATORIES LTD. (IN) | 2011-11-15 | — | — | US | disclosed |
| US-7875730-B2 | Reacting 4-(oxiran-2-ylmethoxy)-9H-carbazole with 2-(2-methoxyphenoxy)ethylamine to make(+-) 1-(9H-carbazol-4-yloxy))-3-[2-(2-methoxyphenoxy)ethyl]amino-2-propanol; nonselective beta -adrenergic activity | CADILA HEALTHCARE LTD. (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7875730-B2 | Reacting 4-(oxiran-2-ylmethoxy)-9H-carbazole with 2-(2-methoxyphenoxy)ethylamine to make(+-) 1-(9H-carbazol-4-yloxy))-3-[2-(2-methoxyphenoxy)ethyl]amino-2-propanol; nonselective beta -adrenergic activity | CADILA HEALTHCARE LTD. (IN) | 2011-01-25 | — | — | US | disclosed |
| US-20090326033-A1 | Carvedilol | HILDESHEIM JEAN | 2009-12-31 | — | — | US | disclosed |
| US-20090326033-A1 | Carvedilol | HILDESHEIM JEAN | 2009-12-31 | — | — | US | disclosed |
| US-20090286991-A1 | PROCESS FOR THE PREPARATION OF CARVEDILOL FORM II | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2009-11-19 | — | — | US | disclosed |
| US-20080207726-A1 | Process for the purification of carvedilol or its salts thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080194838-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-08-14 | — | — | US | disclosed |
| US-20080194838-A1 | CARVEDILOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-08-14 | — | — | US | disclosed |
| WO-2008038301-A1 | A PROCESS FOR THE PREPARATION OF CARVEDILOL | MOREPEN LABORATORIES LIMITED (IN) | 2008-04-03 | — | — | WO | disclosed |
| US-20070055069-A1 | Process for the preparation of carvedilol form-ii | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2007-03-08 | — | — | US | disclosed |
| US-20070055069-A1 | Process for the preparation of carvedilol form-ii | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2007-03-08 | — | — | US | disclosed |
| US-20070027202-A1 | Process for the preparation of carvedilol and its salts | IPCA LABORATORIES LIMITED (IN) | 2007-02-01 | — | — | US | disclosed |
| US-20070027202-A1 | Process for the preparation of carvedilol and its salts | IPCA LABORATORIES LIMITED (IN) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194838-A1 | CARVEDILOL | REN, ADRB1, ADRB2 | ADRB2 3/4885TLR4 3573/4885ADRB3 4/4885 |
| US-20080207726-A1 | Process for the purification of carvedilol or its salts thereof | ADRB2, ADRB1, REN | ADRB2 1/4885TLR4 2563/4885ADRB3 7/4885 |
| US-20070055069-A1 | Process for the preparation of carvedilol form-ii | ADRB2, ADRA2C, AGTR2 | ADRB2 1/4885TLR4 3163/4885ADRB3 6/4885 |
| US-20090326033-A1 | Carvedilol | REN, ADRB1, ADRB2 | ADRB2 3/4885TLR4 3573/4885ADRB3 4/4885 |
| US-20090286991-A1 | PROCESS FOR THE PREPARATION OF CARVEDILOL FORM II | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885TLR4 3067/4885ADRB3 4/4885 |
| US-20070027202-A1 | Process for the preparation of carvedilol and its salts | ADRB2, ADRB3, ADRB1 | ADRB2 1/4885TLR4 2600/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.